(Q34036168)

30 July 2017

6 references

23 March 2019

20 June 2019

22 July 2019

31 July 2019

19 September 2019

23 December 2020

Systematic review of cost and cost-effectiveness of different TB-screening strategies (English)

1 reference

preventive health services

30 July 2017

pulmonary tuberculosis

6 references

23 March 2019

20 June 2019

22 July 2019

31 July 2019

19 September 2019

23 December 2020

1 reference

22 July 2019

1 reference

31 July 2019

biomedical investigative technique

1 reference

cost-effectiveness analysis

19 September 2019

1 reference

1 reference

23 December 2020

1 reference

1

Albert Nienhaus

1 reference

30 July 2017

2

Anja Schablon

1 reference

30 July 2017

4

Roland Diel

1 reference

30 July 2017

3

José Torres Costa

1 reference

PubMed ID

21961888

30 July 2017

language of work or name

1 reference

30 September 2011

7 references

BMC Health Services Research

30 July 2017

23 March 2019

20 June 2019

22 July 2019

31 July 2019

19 September 2019

23 December 2020

7 references

30 July 2017

23 March 2019

20 June 2019

22 July 2019

31 July 2019

19 September 2019

23 December 2020

11

1 reference

30 July 2017

247

1 reference

Creative Commons Attribution 2.0 Generic

30 July 2017

6 references

23 March 2019

20 June 2019

22 July 2019

31 July 2019

19 September 2019

on focus list of Wikimedia project

23 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1472-6963-11-247

0 references

cites work

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Advances in the diagnosis and treatment of tuberculosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Specific immune-based diagnosis of tuberculosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-247

Direct costs of three models for the screening of latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-247

Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-247

Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-247

Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3196701

Cost-optimisation of screening for latent tuberculosis in close contacts

29 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-247

Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany

21 January 2018

1 reference

12 December 2020

Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis

1 reference

12 December 2020

[Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis]

1 reference

12 December 2020

Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan

1 reference

12 December 2020

Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts

1 reference

12 December 2020

German recommendations on health economic evaluation: third and updated version of the Hanover Consensus

1 reference

12 December 2020

The QuantiFERON-TB-GOLD assay for tuberculosis screening in healthcare workers: a cost-comparison analysis

1 reference

12 December 2020

Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6963-11-247

1 reference

PubMed ID

21961888

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference

PubMed ID

21961888